ILCA 2024丨Dr. Tao Peng: New Therapy for Early Multinodular Liver Cancer — Promising Results from Cadonilimab Combined with FOLFOX-HAIC

ILCA 2024丨Dr. Tao Peng: New Therapy for Early Multinodular Liver Cancer — Promising Results from Cadonilimab Combined with FOLFOX-HAIC

2025.02.17
Editor’s Note: Primary hepatocellular carcinoma (HCC) is a prevalent malignant tumor, and combining systemic therapy, immunotherapy, and regional local treatment is guiding HCC clinical treatment to new heights. At the recent 18th International Liver Cancer Association (ILCA) Annual Meeting, Dr. Tao Peng from the Hepatobiliary Surgery Department of The First Affiliated Hospital of Guangxi Medical University shared findings from a preliminary clinical trial targeting multinodular HCC. This study explored the use of cadonilimab (Cadonilimab) combined with the FOLFOX regimen via hepatic artery infusion chemotherapy (HAIC) as a neoadjuvant treatment, aimed at providing a more effective treatment strategy for resectable multinodular HCC patients. Oncology Frontier invited Dr. Tao Peng to discuss the main findings and clinical significance of the study.
Professor Jun Ma: Advancing Frontiers, Updating Guidelines, and Accelerating the Globalization of Hematologic Cancer Treatment

Professor Jun Ma: Advancing Frontiers, Updating Guidelines, and Accelerating the Globalization of Hematologic Cancer Treatment

2025.02.14
From January 17 to 19, 2025, the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Multiple Myeloma Expert Committee Meeting & 2025 CSCO Hematologic Oncology Conference was held in the scenic city of Haikou. This high-profile event brought together leading experts from China and abroad to discuss the latest advances in leukemia, lymphoma, and multiple myeloma, covering both fundamental research and clinical applications. The conference also addressed key challenges in diagnosis and treatment, fostering in-depth discussions among specialists.